{"id":740067,"date":"2023-03-14T16:39:47","date_gmt":"2023-03-14T20:39:47","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-biotech-to-announce-clinical-data-for-the-personalized-dna-cancer-vaccine-evx-02-at-the-2023-american-association-for-cancer-research-annual-meeting-aacr\/"},"modified":"2023-03-14T16:39:47","modified_gmt":"2023-03-14T20:39:47","slug":"evaxion-biotech-to-announce-clinical-data-for-the-personalized-dna-cancer-vaccine-evx-02-at-the-2023-american-association-for-cancer-research-annual-meeting-aacr","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-biotech-to-announce-clinical-data-for-the-personalized-dna-cancer-vaccine-evx-02-at-the-2023-american-association-for-cancer-research-annual-meeting-aacr\/","title":{"rendered":"Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">COPENHAGEN, Denmark, March  14, 2023  (GLOBE NEWSWIRE) &#8212; Evaxion Biotech A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced that the company will present clinical readout of the Phase 1\/2a trial of EVX-02 at the upcoming 2023 American Association for Cancer Research Annual Meeting (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sqeWqDGOrIevIhZ94ltr-XIAvQoxrLaO_CQJ4yT46fn4qq-0trk4MndlG45fbkP-hboo0pmjxd2jjgZ5mjqKhZNf0RqR-kPkIOzbhRvhSsV2tCYJ8sKzTZToJFeP9dX9\" rel=\"nofollow noopener\" target=\"_blank\">2023 AACR<\/a>), taking place from April 14th to April 19th in Orlando, Florida.<\/p>\n<p>\n        <strong>P\u00e9r Norlen, CEO at Evaxion<\/strong>, said: \u201cOur unique AI platform PIONEER has allowed the development of personalized cancer immunotherapies that have the potential to improve the treatment of melanoma as well as of other cancers. We look forward to sharing the clinical phase 1\/2a data of our personalized DNA vaccine EVX-02 with the oncology community during the 2023 AACR meeting.\u201d<\/p>\n<p>\n        <strong>Title: A personalized neoantigen vaccine is well tolerated and induces specific T-cell immune response in patients with resected melanoma<\/strong><br \/>\n        <br \/>\n        <strong>Abstract <\/strong>#: 23-LB-9549-AACR<br \/><strong>Session: <\/strong>Immune response to therapies<br \/><strong>Location:<\/strong> Poster section 35<br \/><strong>Time:<\/strong> Tuesday, April 18, 2023 9:00 AM &#8211; 12:30 PM<\/p>\n<p>\n        <strong>About Evaxion<\/strong><br \/>\n        <br \/>Evaxion Biotech A\/S is a clinical-stage biotech company developing AI-powered immunotherapies. Evaxion\u2019s proprietary and scalable AI technologies decode the human immune system to discover and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has a broad pipeline of product candidates, including three personalized cancer immunotherapies. It is located in H\u00f8rsholm, Denmark, with 70 employees and is listed on the Nasdaq New York stock exchange. For more information, please visit:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LTjsoaR43-M2aDuoHQgxxoHrcsp9ACz5ZhBjIewyROpvvYimWbOV7w1FEjBuNDqY-hHZskc9nD8xf2A-ZnKIqvhiUmL3ZW0Th1mQLUEGBgY=\" rel=\"nofollow noopener\" target=\"_blank\">www.evaxion-biotech.com<\/a>.<\/p>\n<p>\n        <strong>For more information<\/strong><br \/>\n        <br \/>\n        <strong>Per Norl\u00e9n, CEO <\/strong><br \/>\n        <br \/>Evaxion Biotech A\/S<\/p>\n<p>via:<br \/>Katrine Hertz Mortensen<br \/>VP, Communications and Public Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RkTgHmUwbCOEYCRRTAg33vCccbkr-usHDZ1ksWgaeXruaVo45i3OtSmHi140wtny4n3qqNzh3WaSkCNrkOlaB-RgO16tpe_yeWDT1vYXfy4=\" rel=\"nofollow noopener\" target=\"_blank\">khm@evaxion-biotech.com<\/a><br \/>+45 3010 0203<\/p>\n<p>\n        <strong>Forward-looking statement<\/strong><br \/>\n        <br \/>This\u00a0announcement contains forward-looking statements\u00a0within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.\u00a0The words\u00a0\u201ctarget,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201chope,\u201d \u201caim,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201canticipate,\u201d \u201ccontemplate,\u201d \u201ccontinue,\u201d \u201cestimate,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cwill,\u201d \u201ccan have,\u201d \u201clikely,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ccould,\u201d and other words and terms of similar meaning\u00a0identify forward-looking statements.\u00a0Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares,\u00a0the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our\u00a0business from the worldwide COVID-19 pandemic and the ongoing conflict in the region surrounding\u00a0Ukraine\u00a0and\u00a0Russia;\u00a0and other uncertainties affecting our business operations and financial condition.\u00a0For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F\u00a0and other filings\u00a0with the U.S. Securities and Exchange Commission (SEC), which are available at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LTjsoaR43-M2aDuoHQgxxj2GlTFSmsuEt_VUu6zOFr2AH1WycqXOSxBAoG5ikI_25NPJq1jrmNb0Cu-vq274dQ==\" rel=\"nofollow noopener\" target=\"_blank\"><strong><u>www.sec.gov<\/u><\/strong><\/a>.\u00a0We do not assume any obligation to update any forward-looking statements except as required by law.<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc5ODA0MiM0MDE1MDkwNzkjMjI1MjA4Nw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/NTYzYzY1NzMtNDg3NS00YmEzLTlmNGYtNzliZmJiOTg5MDkzLTEyNjM2NDA=\/tiny\/Evaxion-Biotech.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>COPENHAGEN, Denmark, March 14, 2023 (GLOBE NEWSWIRE) &#8212; Evaxion Biotech A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced that the company will present clinical readout of the Phase 1\/2a trial of EVX-02 at the upcoming 2023 American Association for Cancer Research Annual Meeting (2023 AACR), taking place from April 14th to April 19th in Orlando, Florida. P\u00e9r Norlen, CEO at Evaxion, said: \u201cOur unique AI platform PIONEER has allowed the development of personalized cancer immunotherapies that have the potential to improve the treatment of melanoma as well as of other cancers. We look forward to sharing the clinical phase 1\/2a data of our personalized DNA vaccine EVX-02 with &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-biotech-to-announce-clinical-data-for-the-personalized-dna-cancer-vaccine-evx-02-at-the-2023-american-association-for-cancer-research-annual-meeting-aacr\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-740067","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-biotech-to-announce-clinical-data-for-the-personalized-dna-cancer-vaccine-evx-02-at-the-2023-american-association-for-cancer-research-annual-meeting-aacr\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"COPENHAGEN, Denmark, March 14, 2023 (GLOBE NEWSWIRE) &#8212; Evaxion Biotech A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced that the company will present clinical readout of the Phase 1\/2a trial of EVX-02 at the upcoming 2023 American Association for Cancer Research Annual Meeting (2023 AACR), taking place from April 14th to April 19th in Orlando, Florida. P\u00e9r Norlen, CEO at Evaxion, said: \u201cOur unique AI platform PIONEER has allowed the development of personalized cancer immunotherapies that have the potential to improve the treatment of melanoma as well as of other cancers. We look forward to sharing the clinical phase 1\/2a data of our personalized DNA vaccine EVX-02 with &hellip; Continue reading &quot;Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-biotech-to-announce-clinical-data-for-the-personalized-dna-cancer-vaccine-evx-02-at-the-2023-american-association-for-cancer-research-annual-meeting-aacr\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-14T20:39:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc5ODA0MiM0MDE1MDkwNzkjMjI1MjA4Nw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-biotech-to-announce-clinical-data-for-the-personalized-dna-cancer-vaccine-evx-02-at-the-2023-american-association-for-cancer-research-annual-meeting-aacr\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-biotech-to-announce-clinical-data-for-the-personalized-dna-cancer-vaccine-evx-02-at-the-2023-american-association-for-cancer-research-annual-meeting-aacr\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)\",\"datePublished\":\"2023-03-14T20:39:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-biotech-to-announce-clinical-data-for-the-personalized-dna-cancer-vaccine-evx-02-at-the-2023-american-association-for-cancer-research-annual-meeting-aacr\\\/\"},\"wordCount\":567,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-biotech-to-announce-clinical-data-for-the-personalized-dna-cancer-vaccine-evx-02-at-the-2023-american-association-for-cancer-research-annual-meeting-aacr\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDc5ODA0MiM0MDE1MDkwNzkjMjI1MjA4Nw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-biotech-to-announce-clinical-data-for-the-personalized-dna-cancer-vaccine-evx-02-at-the-2023-american-association-for-cancer-research-annual-meeting-aacr\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-biotech-to-announce-clinical-data-for-the-personalized-dna-cancer-vaccine-evx-02-at-the-2023-american-association-for-cancer-research-annual-meeting-aacr\\\/\",\"name\":\"Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-biotech-to-announce-clinical-data-for-the-personalized-dna-cancer-vaccine-evx-02-at-the-2023-american-association-for-cancer-research-annual-meeting-aacr\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-biotech-to-announce-clinical-data-for-the-personalized-dna-cancer-vaccine-evx-02-at-the-2023-american-association-for-cancer-research-annual-meeting-aacr\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDc5ODA0MiM0MDE1MDkwNzkjMjI1MjA4Nw==\",\"datePublished\":\"2023-03-14T20:39:47+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-biotech-to-announce-clinical-data-for-the-personalized-dna-cancer-vaccine-evx-02-at-the-2023-american-association-for-cancer-research-annual-meeting-aacr\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-biotech-to-announce-clinical-data-for-the-personalized-dna-cancer-vaccine-evx-02-at-the-2023-american-association-for-cancer-research-annual-meeting-aacr\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-biotech-to-announce-clinical-data-for-the-personalized-dna-cancer-vaccine-evx-02-at-the-2023-american-association-for-cancer-research-annual-meeting-aacr\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDc5ODA0MiM0MDE1MDkwNzkjMjI1MjA4Nw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDc5ODA0MiM0MDE1MDkwNzkjMjI1MjA4Nw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-biotech-to-announce-clinical-data-for-the-personalized-dna-cancer-vaccine-evx-02-at-the-2023-american-association-for-cancer-research-annual-meeting-aacr\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-biotech-to-announce-clinical-data-for-the-personalized-dna-cancer-vaccine-evx-02-at-the-2023-american-association-for-cancer-research-annual-meeting-aacr\/","og_locale":"en_US","og_type":"article","og_title":"Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR) - Market Newsdesk","og_description":"COPENHAGEN, Denmark, March 14, 2023 (GLOBE NEWSWIRE) &#8212; Evaxion Biotech A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced that the company will present clinical readout of the Phase 1\/2a trial of EVX-02 at the upcoming 2023 American Association for Cancer Research Annual Meeting (2023 AACR), taking place from April 14th to April 19th in Orlando, Florida. P\u00e9r Norlen, CEO at Evaxion, said: \u201cOur unique AI platform PIONEER has allowed the development of personalized cancer immunotherapies that have the potential to improve the treatment of melanoma as well as of other cancers. We look forward to sharing the clinical phase 1\/2a data of our personalized DNA vaccine EVX-02 with &hellip; Continue reading \"Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-biotech-to-announce-clinical-data-for-the-personalized-dna-cancer-vaccine-evx-02-at-the-2023-american-association-for-cancer-research-annual-meeting-aacr\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-14T20:39:47+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc5ODA0MiM0MDE1MDkwNzkjMjI1MjA4Nw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-biotech-to-announce-clinical-data-for-the-personalized-dna-cancer-vaccine-evx-02-at-the-2023-american-association-for-cancer-research-annual-meeting-aacr\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-biotech-to-announce-clinical-data-for-the-personalized-dna-cancer-vaccine-evx-02-at-the-2023-american-association-for-cancer-research-annual-meeting-aacr\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)","datePublished":"2023-03-14T20:39:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-biotech-to-announce-clinical-data-for-the-personalized-dna-cancer-vaccine-evx-02-at-the-2023-american-association-for-cancer-research-annual-meeting-aacr\/"},"wordCount":567,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-biotech-to-announce-clinical-data-for-the-personalized-dna-cancer-vaccine-evx-02-at-the-2023-american-association-for-cancer-research-annual-meeting-aacr\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc5ODA0MiM0MDE1MDkwNzkjMjI1MjA4Nw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-biotech-to-announce-clinical-data-for-the-personalized-dna-cancer-vaccine-evx-02-at-the-2023-american-association-for-cancer-research-annual-meeting-aacr\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-biotech-to-announce-clinical-data-for-the-personalized-dna-cancer-vaccine-evx-02-at-the-2023-american-association-for-cancer-research-annual-meeting-aacr\/","name":"Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-biotech-to-announce-clinical-data-for-the-personalized-dna-cancer-vaccine-evx-02-at-the-2023-american-association-for-cancer-research-annual-meeting-aacr\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-biotech-to-announce-clinical-data-for-the-personalized-dna-cancer-vaccine-evx-02-at-the-2023-american-association-for-cancer-research-annual-meeting-aacr\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc5ODA0MiM0MDE1MDkwNzkjMjI1MjA4Nw==","datePublished":"2023-03-14T20:39:47+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-biotech-to-announce-clinical-data-for-the-personalized-dna-cancer-vaccine-evx-02-at-the-2023-american-association-for-cancer-research-annual-meeting-aacr\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-biotech-to-announce-clinical-data-for-the-personalized-dna-cancer-vaccine-evx-02-at-the-2023-american-association-for-cancer-research-annual-meeting-aacr\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-biotech-to-announce-clinical-data-for-the-personalized-dna-cancer-vaccine-evx-02-at-the-2023-american-association-for-cancer-research-annual-meeting-aacr\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc5ODA0MiM0MDE1MDkwNzkjMjI1MjA4Nw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDc5ODA0MiM0MDE1MDkwNzkjMjI1MjA4Nw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-biotech-to-announce-clinical-data-for-the-personalized-dna-cancer-vaccine-evx-02-at-the-2023-american-association-for-cancer-research-annual-meeting-aacr\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/740067","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=740067"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/740067\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=740067"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=740067"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=740067"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}